Bausch Health Companies Inc. (NYSE:BHC) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its holdings in Bausch Health Companies Inc. (NYSE:BHC) by 7.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 318,736 shares of the company’s stock after selling 26,168 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.09% of Bausch Health Companies worth $2,601,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in BHC. Headlands Technologies LLC acquired a new position in Bausch Health Companies in the second quarter valued at $35,000. MQS Management LLC purchased a new stake in shares of Bausch Health Companies during the 2nd quarter valued at about $71,000. Certuity LLC purchased a new position in Bausch Health Companies in the 2nd quarter worth approximately $75,000. Bfsg LLC raised its stake in shares of Bausch Health Companies by 46.7% during the second quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after purchasing an additional 3,643 shares during the period. Finally, Kendall Capital Management purchased a new position in shares of Bausch Health Companies in the second quarter valued at $87,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Royal Bank of Canada raised their price target on shares of Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research report on Friday, November 1st. Evercore ISI raised Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Finally, StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.75.

Bausch Health Companies Trading Up 0.8 %

Shares of Bausch Health Companies stock opened at $7.81 on Friday. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of -16.27 and a beta of 0.69. Bausch Health Companies Inc. has a twelve month low of $3.96 and a twelve month high of $11.46. The business’s 50 day simple moving average is $8.38 and its 200-day simple moving average is $7.24.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The firm had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period last year, the firm posted $1.03 EPS. Bausch Health Companies’s quarterly revenue was up 12.2% compared to the same quarter last year. Sell-side analysts predict that Bausch Health Companies Inc. will post 3.74 earnings per share for the current year.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.